In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Lilly Out, Amylin’s Future Is Tied To Bydureon

Executive Summary

With the unwinding of its once-lucrative nine-year partnership with Eli Lilly, Amylin Pharmaceuticals now carries all the risk – and all the reward – of its exenatide franchise for diabetes. With sole ownership of its exenatide franchise, Amlyin now has the freedom to seek a lucrative partnership or opt to sell the company outright to a large pharma seeking an edge in a growing diabetes market.


Related Content

AstraZeneca Hopes Bydureon Pen Will Rewrite GLP-1 Story
Biopharma Quarterly Deal Statistics, Q1 2012
Icahn Turns Up The Heat On Amylin, Urges Board To Sell
Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target
Pressure Mounts For Amylin As Bydureon PDUFA Approaches
In Advance Of Pharma Partnership, Intarcia Inks Equity Deal With Quintiles
Amylin's Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle
Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts